^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Labvax 3(22)-23

    i
    Other names: Labvax 3(22)-23
    Associations

    News

    Trials
    Company:
    LabyRx Immuno-Oncology
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    1year
    A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=77, Recruiting, Tianhong Li | Phase classification: P1 --> P1/2 | N=10 --> 77 | Trial completion date: Sep 2027 --> Jan 2030 | Trial primary completion date: Sep 2023 --> Jan 2026
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF mutation • MET mutation
    |
    Keytruda (pembrolizumab) • Labvax 3(22)-23 • Leukine (sargramostim)
    over2years
    A first-in-human, phase I, open-label study of a novel cancer vaccine labvax 3(22)-23 and adjuvant GM-CSF in patients with advanced stage adenocarcinomas. (ASCO 2022)
    Sargramostim, a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF), is given as an immunostimulator with LabVax 3(22)-23 to boost the antitumor immune response. After completion of study treatment, patients are followed every 3 months for 1 year. Two patients are enrolled at the time of submission.
    Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CSF2 (Colony stimulating factor 2)
    |
    PD-L1 expression
    |
    Labvax 3(22)-23 • Leukine (sargramostim)